Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation. 1986

J Rajantie, and G E Sale, and H J Deeg, and D Amos, and F Appelbaum, and R Storb, and R A Clift, and C D Buckner

We reviewed the records and marrow biopsy specimens of 75 patients with leukemic, myelodysplastic, or myeloproliferative disorders to determine whether the presence of marrow fibrosis affected engraftment after allogeneic marrow transplantation. While 28 control patients without fibrosis achieved prompt engraftment, two of 32 patients (6%) with mild and five of 15 patients (33%) with severe fibrosis failed. The rate of myeloid recovery was significantly slower and the dependence on platelet and red blood cell transfusions was significantly longer in patients with severe fibrosis than in patients with no fibrosis. A finding of severe marrow fibrosis should therefore be taken into account when evaluating the risks and benefits of marrow transplantation.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D009196 Myeloproliferative Disorders Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE. Disorder, Myeloproliferative,Disorders, Myeloproliferative,Myeloproliferative Disorder
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J Rajantie, and G E Sale, and H J Deeg, and D Amos, and F Appelbaum, and R Storb, and R A Clift, and C D Buckner
October 1983, Experimental hematology,
J Rajantie, and G E Sale, and H J Deeg, and D Amos, and F Appelbaum, and R Storb, and R A Clift, and C D Buckner
April 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J Rajantie, and G E Sale, and H J Deeg, and D Amos, and F Appelbaum, and R Storb, and R A Clift, and C D Buckner
January 1991, Ugeskrift for laeger,
J Rajantie, and G E Sale, and H J Deeg, and D Amos, and F Appelbaum, and R Storb, and R A Clift, and C D Buckner
May 1986, Transplantation,
J Rajantie, and G E Sale, and H J Deeg, and D Amos, and F Appelbaum, and R Storb, and R A Clift, and C D Buckner
January 1989, Leukemia research,
J Rajantie, and G E Sale, and H J Deeg, and D Amos, and F Appelbaum, and R Storb, and R A Clift, and C D Buckner
August 1985, Transplantation,
J Rajantie, and G E Sale, and H J Deeg, and D Amos, and F Appelbaum, and R Storb, and R A Clift, and C D Buckner
October 1982, British journal of haematology,
J Rajantie, and G E Sale, and H J Deeg, and D Amos, and F Appelbaum, and R Storb, and R A Clift, and C D Buckner
January 1991, Schweizerische medizinische Wochenschrift. Supplementum,
J Rajantie, and G E Sale, and H J Deeg, and D Amos, and F Appelbaum, and R Storb, and R A Clift, and C D Buckner
July 2000, Bone marrow transplantation,
J Rajantie, and G E Sale, and H J Deeg, and D Amos, and F Appelbaum, and R Storb, and R A Clift, and C D Buckner
January 1985, Clinical pharmacy,
Copied contents to your clipboard!